NUEDEXTA IS AFFORDABLE AND ACCESSIBLE

Actor portrayal of affordable and accessible PseudoBulbar Affect (PBA) treatment

Considerable savings and coverage for commercial patients1,2

  • 81% of commercially insured patients pay ≤ $30 for a NUEDEXTA prescription1
  • NUEDEXTA has preferred brand coverage for more than 100 million commercial lives2

Extensive nationwide Medicare coverage3

  • 80% of Medicare Part D patients pay ≤ $15 for a NUEDEXTA prescription1,a
  • NUEDEXTA is covered by >99% of all Medicare plans nationwide, including3
    • Medicare Prescription Drug Plans (PDP)
    • Medicare Advantage Plans (MA)
    • Special Needs Plans (SN)

aApril-June 2018.

NUEDEXTA sample bottle for PseudoBulbar Affect (PBA) patients
REQUEST SAMPLES
Request a sample to start your patients on NUEDEXTA. Eligible healthcare providers can request a free 10-day sample of NUEDEXTA for appropriate patients.

NUEDEXTA Co-Pay Savings Card

NUEDEXTA $0 Co-Pay Card

CARD MUST BE ACTIVATED BEFORE USE.

Visit nuedexta.com/activate or call 1-855-468-3339

CO-PAY SAVINGS PROGRAM:

By enrolling, your commercially insured patients may pay as little as $0 for a 90-day supply, or $30 for a 30-day supply.

  • Maximum benefit is $250
  • Applies to both new prescription and refills
  • Patients who are eligible for any state or federally funded prescription programs, including Medicare, Medicaid, Medigap, VA, DOD, or TriCare, are not eligible for this program

Print Co-Pay Card Now

Resources for you and your patients

Example of Pseudobulbar Affect screening questionaire
PBA Screening Questionnaire
Measure symptoms suggestive of pseudobulbar affect (PBA) with this CNS-LS patient-administered questionnaire developed by the Center for Neurologic Study.
Nuedexta Psuedobulbar Affect Patient Brochure
NUEDEXTA Patient Brochure
Share this informational brochure with your patients to learn about NUEDEXTA, the first and only FDA-approved treatment for PBA.
NUEDEXTA Brochure for Long-term Care Residents
NUEDEXTA Brochure for Long-term Care Residents

Share this informational brochure with caregivers of long-term care residents to educate them about PBA and NUEDEXTA, the first and only FDA-approved treatment for PBA, and how to talk with a healthcare provider if it may be appropriate for their loved ones.

NUEDEXTA®️ Sample Letters of Medical Necessity
NUEDEXTA Sample Letters of Medical Necessity

The Sample Letters of Medical Necessity are templates of letters that can be used to provide a payer with additional information about the need for a patient to use NUEDEXTA. Choose the appropriate template to use based upon the payer request.

Download Basic Letter Download Comprehensive Letter

Avanir helps patients get the medicine they need

Advanced Patient Services

The Advanced Patient Services (APS) program is designed to help patients and caregivers appropriately navigate the complexities of the managed care landscape to obtain NUEDEXTA.

REIMBURSEMENT SUPPORT b
  • Benefits verification
  • Patient Assistance Program (PAP)
  • Referrals to independent foundations
  • Prior authorization and formulary exception support
  • Home delivery
Advanced Patient Services

Call 1-855-4NUEDEX
(1-855-468-3339)

Monday through Friday | 8 AM – 7 PM ET

Download the APS enrollment form to get your patients started AdvancedPatientServices.com

CoverMyMeds

CoverMyMeds is a free online tool that streamlines the prior authorization (PA) process for providers and pharmacists.

PRIOR AUTHORIZATION SUPPORT b
  • Process requests for any medication and health plans
  • Create PA renewals from previously submitted requests
  • Receive faster PA determinations, often in real time
CoverMyMeds

Call 1-866-452-5017 for assistance

Register at covermymeds.com

bSome services are limited to approved indications or program terms.

References: 1. Precision Xtract, April 2018-June 2018. 2. Decision Resources Group. NUEDEXTA Preferred Commercial Coverage. January 14, 2019. 3. Decision Resources Group. NUEDEXTA Medicare Coverage. January 14, 2019.

INDICATION AND USAGE

NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurologic disease or injury.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Quinidine and Related Drugs: NUEDEXTA contains quinidine, and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine.

Hypersensitivity: NUEDEXTA is contraindicated in patients with a history of NUEDEXTA-, quinine-, mefloquine-, or quinidine-induced thrombocytopenia, hepatitis, bone-marrow depression, lupus-like syndrome, or known hypersensitivity to dextromethorphan (eg, rash, hives).

MAOIs: NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), or in patients who have taken MAOIs within the preceding 14 days, due to the risk of serious and possibly fatal drug interactions, including serotonin syndrome. Allow at least 14 days after stopping NUEDEXTA before starting an MAOI.

Cardiovascular: NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, heart failure, patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (eg, thioridazine and pimozide), patients with complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block.

WARNINGS AND PRECAUTIONS

Thrombocytopenia and Other Hypersensitivity Reactions: Quinidine can cause immune-mediated thrombocytopenia that can be severe or fatal. Non-specific symptoms, such as lightheadedness, chills, fever, nausea, and vomiting, can precede or occur with thrombocytopenia. NUEDEXTA should be discontinued immediately if thrombocytopenia occurs.

Hepatotoxicity: Hepatitis, including granulomatous hepatitis, has been reported in patients receiving quinidine, generally during the first few weeks of therapy. Discontinue immediately if this occurs.

Cardiac Effects: NUEDEXTA causes dose-dependent QTc prolongation. QT prolongation can cause torsades de pointes–type ventricular tachycardia, with the risk increasing as the degree of prolongation increases. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3 to 4 hours after the first dose. Some risk factors include use with CYP3A4 inhibitors or drugs that prolong QT interval, electrolyte abnormalities, bradycardia, or left ventricular hypertrophy or dysfunction. If patients taking NUEDEXTA experience symptoms that could indicate the occurrence of cardiac arrhythmias (eg, syncope or palpitations), NUEDEXTA should be discontinued, and the patient further evaluated.

Concomitant Use of CYP2D6 Substrates: NUEDEXTA inhibits CYP2D6 and may interact with other drugs metabolized by CYP2D6. Adjust dose of CYP2D6 substrates as needed.

Dizziness: NUEDEXTA may cause dizziness. Take precautions to reduce the risk of falls.

Serotonin Syndrome: Use of NUEDEXTA with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants increases the risk of “serotonin syndrome.”

Anticholinergic Effects of Quinidine: Monitor for worsening in myasthenia gravis.

ADVERSE REACTIONS

The most common adverse reactions (incidence of ≥3% and two-fold greater than placebo) in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence.

These are not all the risks for use of NUEDEXTA. Please see Full Prescribing Information.

Co-Pay/Sample Requests